Role of bone markers in monitoring the therapeutic effect of bisphosphonates in postmenopausal osteoporosis

Selma Agić-Bilalagić, Amela Begić, Šejla Cerić, Elma Kučukalić-Selimović


Objective: Aim of the study was to detect values of bone markers
as a way to reflect response to therapy in osteoporosis .
Materials and methods: The study involved data of 73 female
patients suffering from postmenopausal osteoporosis that were
treated with bisphosphonates in the period of twelve months.
Values of osteocalcin, P1NP and β-Cross Laps were measured
before starting therapy, six months and twelve months after the
start of therapy. Bone mass density (BMD) was measured with
densitometry before therapy and twelve months after the start
of therapy. Values of bone markers were determined by in vitro
quantitative determination in human serum and plasma. Data
base was configured in Microsoft Office Excel 2010. Statistical
analysis was done by IBM SPSS Statistics v. 21.0 for Windows
programme. Data was represented in table and graph form with
help of classic methods of descriptive statistics.
Results: Results in this study have showed significant reduction
in serum values of bone formation markers (osteocalcin, P1NP)
and also bone resorption markers (β-cross laps) after inducing
bisphosphonate therapy in patients with postmenopausal osteoporosis
during a period of 12 months.Results have also showed
significant increase in bone mass density respectively increase
in vertebral T-score values and also increase in femoral T-score
Conclusion: dinamics of bone markers significantly reflects
therapeutic effect of bisphosphonate therapy in postmenopausal
Keywords: osteoporosis, therapy, bisphosphonates, P1NP, osteocalcin,
β-Cross Laps

Full Text:



E.Kucukalic-Selimovic i saradnici. Osteoporoza, dijagnostika,

prevencija i liječenje. Institut za naučnoistraživački rad i

razvoj KCUS. Sarajevo 2008., 23-25

J.E.Henderson, D.Goltzman. Osteoporosis Primer. Cambridge

University Press, 2004., ,1-2

Pisani P, Renna MD, Conversano F, et al. Major osteoporotic

fragility fractures: Risk factor updates and societal impact.

World J Orthop. 2016;7(3):171-81. Published 2016 Mar

S.H.Gueldner, T.N.Grabo, E.D.Newman, D.R. Cooper;

Osteoporosis : clinical guidelines for prevention, diagnosis,

and management. Springer Publishing Company, New York,

E. Michael Lewiecki, Bisphosphonates for the treatment of

osteoporosis: insights for clinicians, Therapeutic Advances in

Chronic Disease, 2010 May; 1(3): 115–128

Clinical guideline for the prevention and treatment of osteoporosis

in postmenopausal women and older men (RACGP)

[Updated on Feb 2010].


E.M. Lewiecki. Bone Density Testing to Monitor Osteoporosis

Therapy in Clinical Practice. Am Fam Physician. 2010

Oct 1;82(7):749-50.

P. Ravn , D. Hosking , D. Thompson , G. Cizza , R. D.

Wasnich , M. McClung , A. J. Yates , N. H. Bjarnason , C.

Christiansen; Monitoring of Alendronate Treatment and

Prediction of Effect on Bone Mass by Biochemical Markers

in the Early Postmenopausal Intervention Cohort Study;

The Journal of Clinical Endocrinology & Metabolism, List

of Issues; Volume 84, Issue 7 pp. 2363–2368

Ivana Čepelak, Dubravka Čvorišćec. Biokemijski biljezi pregradnje

kostiju – pregled. Biochemia Medica, Vol. 19 No. 1,

, 17-35

S. Vasikaran, C. Cooper, R. Eastell, A. Griesmacher, H. A.

Morris, T. Trenti, International Osteoporosis Foundation

and International Federation of Clinical Chemistry and

Laboratory Medicine Position on bone marker standards

in osteoporosis, Clinical Chemistry and Laboratory Medicine,

Volume 49, Issue 8, 1271–1274

Burgeson RE. New collagens, new concepts. Ann Rev Cell

Biol 1988; 4;551-577

Bonnick SL, Shulman L. Monitoring osteoporosis therapy:

bone mineral density, bone turnover markers, or both?Am J

Med. 2006 Apr;119(4 Suppl 1):S25-31.


Folia Med. Fac. Med. Univ. Saraeviensis 2018; 53(1): 12-17

Cremers S et al. Biochemical Markers of Bone Turnover in

the Clinical Development of Drugs for Osteoporosis and

Metastatic Bone Disease. Drugs 2006;66:2031–58

National Osteoporosis Foundation. Clinician’s Guide to

Prevention and Treatment of Osteoporosis. 2008. http://

Ravn P , Bisphosphonates for prevention of postmenopausal

osteoporosis. Dan Med Bull. 2002 Feb;49(1):1-18.

H.G. Bone, D.Hosking,JP. Devogelaer, J. R. Tucci,R. D.

Emkey, R. P. Tonino, J.A.Rodriguez-Portales, R.W. Downs,

J. Gupta, A. C. Santora,U. A. Liberman Ten Years’ Experience

with Alendronate for Osteoporosis in Postmenopausal

Women; N Engl J Med 2004; 350:1189-1199

Sirpa Eviö, Aila Tiitinen, Kalevi Laitinen, Olavi Ylikorkala,

and Matti J. Välimäki Effects of Alendronate and Hormone

Replacement Therapy, Alone and in Combination, on Bone

Mass and Markers of Bone Turnover in Elderly Women with

Osteoporosis; The Journal of Clinical Endocrinology & Metabolism,

Volume 89, Issue 2 pp. 626–631

E.Kučukalić-Selimović, A. Valjevac , A.Hadžović-Džuvo,

A. Skopljak-Beganović, R. Alimanovic-Alagić, A. Brković:

Evaluation of bone remodelling parameters after one year

treatment with alendronate in postmenopausal women with

osteoporosis. Bosnian Journal of Basic Medical Sciences,

; 11 (1)

Pyon EY , Once-monthly ibandronate for postmenopausal

osteoporosis: review of a new dosing regimen. Clin

Ther. 2006 Apr;28(4):475-90.

P. Ravn, B. Clemmesen, B.J. Riis, Christiansen C. The effect

on bone mass and bone markers of different doses of ibandronate:

A new bisphosphonate for prevention and treatment

of postmenopausal osteoporosis: A 1-year, randomized, double-

blind, placebo-controlled dose-finding study, Bone, Volume

, Issue 5, 527–533


  • There are currently no refbacks.